Pregnancy outcome following first trimester exposure to sumatriptan.

作者信息

Shuhaiber S, Pastuszak A, Schick B, Matsui D, Spivey G, Brochu J, Koren G

机构信息

The Motherisk Program, Department of Pediatrics and Research Institute, The Hospital for Sick Children and the University of Toronto, Ontario, Canada.

出版信息

Neurology. 1998 Aug;51(2):581-3. doi: 10.1212/wnl.51.2.581.

DOI:10.1212/wnl.51.2.581

PMID:9710039

Abstract

We prospectively compared pregnancy outcome after exposure to sumatriptan with that of disease-matched controls and nonteratogen controls. There were no differences in the rates of live births, spontaneous abortions, therapeutic abortions, or major birth defects among the three groups. This first prospective report suggests that the use of sumatriptan during organogenesis is not associated with an apparent increased risk of major birth defects.

摘要